Wedbush Securities just reaffirmed its bullish stance on Tesla (NASDAQ: TSLA) with an Outperform rating and $500 price target, even as the latest feud between CEO Elon Musk and President Donald Trump threatens to derail the regulatory progress Tesla needs for its autonomous driving ambitions.The update comes as Tesla shares continue their recent slide. The stock dropped 1.84% to close at $317.66 on Monday, capping off a brutal week that saw shares fall over 10%. Pre-market trading brought more pain, with sh ...

Alphabet (GOOG 1.74%) (GOOGL 1.69%) is perhaps the least-loved "Magnificent Seven" stock of all. Many investors are fearful of its base business being disrupted by generative AI products, but that weakness hasn't surfaced yet. Additionally, Alphabet has some other business units that are cashing in on the AI arms race and boosting its overall growth.Alphabet's stock appears absurdly cheap right now, and investors willing to buck the trend can find huge value in its shares. Alphabet's base business is still ...

Core Insights - The article discusses common pitfalls in growth strategies that companies often encounter, emphasizing the importance of understanding product-market fit and avoiding blind reliance on external growth tactics. Group 1: Common Growth Pitfalls - Companies often blame their go-to-market (GTM) strategy for product failures, neglecting the need for genuine product-market fit (PMF) before scaling [7][10]. - Relying solely on a growth team to reverse declining performance is ineffective; identifying core issues within the product or organization is crucial [13][15]. - Companies mistakenly believe that rebranding will lead to immediate growth, but such efforts often yield minimal short-term results [19][21]. Group 2: Misguided Strategies - Copying competitors' successful strategies can lead to mediocrity, as each company's context and customer base are unique [24][28]. - Companies often perceive their growth challenges as unique, overlooking the fact that many have faced similar issues and can provide valuable insights [29][31]. - Over-reliance on third-party channels for customer acquisition can be detrimental; companies should focus on building their own channels [33][35]. Group 3: Growth Model Limitations - Sticking to a single growth model without adaptation can lead to diminishing returns; companies must continuously explore new strategies [38][40]. - Companies often attempt to handle all challenges internally, missing out on the benefits of external expertise and insights [43][45]. - Excessive focus on A/B testing can slow down progress; a balance between data-driven decisions and intuitive understanding of the market is necessary [48][49]. Group 4: Key Growth Strategies - Implementing growth loops instead of traditional funnel thinking can create sustainable growth engines [56]. - Utilizing the racecar framework helps categorize different growth activities and their interrelations [57][60]. - Engaging adjacent users can unlock new growth opportunities without needing to expand the existing PMF [61].

space race stonk!Kyle (@0xkyle__):2021 is knocking at the door https://t.co/KYOk30bWGp ...

united states government confirmed aliens are real and you don't own the space race stonk? ...

Circle retraces to $220 https://t.co/cXMnx4xhuE ...

Core Insights - Aethlon Medical has achieved a significant milestone by treating the second patient with the Hemopurifier in its clinical trial for solid tumors not responding to anti-PD-1 antibodies [1][2] - The trial aims to assess the safety and feasibility of the Hemopurifier, with the first cohort consisting of approximately 18 patients [6] - The Hemopurifier is designed to remove tumor-derived extracellular vesicles (EVs) from the bloodstream, potentially improving responses to anti-PD-1 therapies [5][7] Group 1: Clinical Trial Progress - The second patient was treated on June 11, 2025, at the Royal North Shore Hospital/University of Sydney, following the first patient treated on January 29, 2025 [1][2] - Both patients completed the 4-hour Hemopurifier treatment without device deficiencies or immediate complications, and have finished the 7-day safety follow-up period [2][4] - The Data Safety Monitoring Board (DSMB) will review the safety data after the third patient is enrolled, which is expected to occur soon [3][4] Group 2: Device and Mechanism - The Hemopurifier is an investigational device that utilizes plasma separation and affinity binding to remove enveloped viruses and EVs from circulation [7][8] - Preclinical studies indicate that the Hemopurifier can reduce the number of exosomes in cancer patient plasma, which may enhance the effectiveness of anti-PD-1 therapies [5][6] - The device holds FDA Breakthrough Device designation for treating advanced or metastatic cancer patients who are unresponsive to standard therapies [8] Group 3: Future Directions - The primary endpoint of the trial is to monitor adverse events and significant changes in safety lab tests among treated patients [6] - The study will also explore the number of Hemopurifier treatments required to decrease EV concentrations and whether this improves the immune response against tumor cells [6] - Data on the effects of the Hemopurifier on anti-tumor T cell activity is anticipated approximately three months after the enrollment of the third patient [3]

Oh, here we go. Here we go. Oh my God, this is crazy.Hey everyone Today I'm here with Google Gemini and we are going to have some fun with Veo 3. Let's make some racetracks I'm going to go for, “Underwater racetrack with dolphins a papaya car with a snorkel. ” Why not.Oh, here we go. Here we go. Oh, my god, this is crazy.The car is a papaya. Let's make it real crazy. “A race track on a volcano And 50 very angry.” piranhas. Why not. “.chasing you. ” Let's see what you got for me now. If it manages to make so ...

Michelle Gatting, an official Porsche factory driver, talks about what it's like racing in the 24 hours of Le Mans auto race. She is on "Bloomberg Open Interest." -------- More on Bloomberg Television and Markets Like this video? Subscribe and turn on notifications so you don't miss any videos from Bloomberg Markets & Finance: https://tinyurl.com/ysu5b8a9 Visit http://www.bloomberg.com for business news & analysis, up-to-the-minute market data, features, profiles and more. Connect with Bloomberg Television ...

So, Todd, this is not a done deal. It's still in the early consideration stages. But your reporting shows we're talking about the IRS, which is part of the Treasury Department.How far along the process do we think they are. It's unclear. We just know that the Treasury is considering these proposals.The Office of Tax Policy, where, you know, these sorts of rules are normally drafted and considered is, you know, you know, discussing the possibility of codifying, you know, what Trump has threatened Harvard wit ...